RET and neuroendocrine neoplasm: Of note, small-cell lung cancer (SCLC), a high-grade neuroendocrine tumor, has also been associated with RET activating mutations although to a far lesser degree than nearly universal TP53 and RB loss-of-function mutations [59,67].